Coratti, G., Bovis, F., Pane, M., Pasternak, A., Albamonte, E., Mizzoni, I., Glanzman, A. M., Morando, S., Montes, J., Cavallina, I., Dunaway Young, S., Duong, T., Rolle, E., Civitello, M., De Sanctis, R., Bravetti, C., Ricci, F., Gadaleta, G., … Mongini, T. (2025). Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. European Journal of Neurology, 32(7). Portico. https://doi.org/10.1111/ene.70268

Pasternak, A., McDermott, M. P., Montes, J., Glanzman, A. M., Coratti, G., Dunaway Young, S., Duong, T. T., Martens, W. B., Day, J. W., Zolkipli-Cunningham, Z., Sansone, V. A., D’Amico, A., Messina, S., Bruno, C., Mercuri, E., De Vivo, D. C., & Darras, B. T. (2025). Spinal Muscular Atrophy Functional Composite Score Revised (SMA-FCR) in Untreated and Nusinersen-Treated Patient Cohorts. Neurology, 105(2). https://doi.org/10.1212/wnl.0000000000213839

Coratti, G., Civitello, M., Rohwer, A., Salmin, F., Glanzman, A. M., Montes, J., Pasternak, A., De Sanctis, R., Young, S. D., Duong, T., Mizzoni, I., Milev, E., Sframeli, M., Morando, S., Albamonte, E., D’Amico, A., Brolatti, N., Pane, M., Scoto, M., … Mercuri, E. (2024). Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA. Neuromuscular Disorders, 41, 42–50. https://doi.org/10.1016/j.nmd.2024.05.003

Rudchenko, S., Taylor, S., Milosavic, N., Rudchenko, M., Wedderhoff Tissi, B., Mapara, M. Y., & Stojanovic, M. N. (2023). Amplification of Signal on Cell Surfaces in Molecular Cascades. Cells, 12(24), 2858. https://doi.org/10.3390/cells12242858

Klein, H.-U. (2023). demuxmix: demultiplexing oligonucleotide-barcoded single-cell RNA sequencing data with regression mixture models. Bioinformatics, 39(8). https://doi.org/10.1093/bioinformatics/btad481

Brannagan, T. H., Coelho, T., Wang, A. K., Polydefkis, M. J., Dyck, P. J., Berk, J. L., Drachman, B., Gorevic, P., Whelan, C., Conceição, I., Plante-Bordeneuve, V., Merlini, G., Obici, L., Plana, J. M. C., Gamez, J., Kristen, A. V., Mazzeo, A., Gentile, L., … Narayana, A. (2022). Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. Journal of Neurology, 269(12), 6416–6427. https://doi.org/10.1007/s00415-022-11276-8